HCHugo F. Costa-Almeida

Hugo F. Costa-Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hugo F. Costa-Almeida has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual-Acting Vitamin B 3 -Melanostatin Neuropeptide Hybrids as Potent Modulators of the Dopamine D 2 Receptors with Neuroprotective Activity

    by Beatriz L. Pires-Lima, Sara C. Silva-Reis, Xavier Cruz Correia, Hugo F. Costa-Almeida, Vera M. Costa, Xerardo García-Mera, José Brea, María I. Loza, Marialessandra Contino, Maria Grazia Perrone, et al.

    Parkinson's disease (PD) therapy remains limited by complications of the levodopa regimen, highlighting the need for novel therapeutic strategies to modulate dopaminergic signaling. Melanostatin (MIF-1) has attracted attention as a privileged scaffold for dopamine D2 receptor (D2R) modulation due to its intrinsic positive allosteric modulatory activity, although improved potency and drug-like properties are required for translation. In this work, nicotinic acid (Nic), a vitamer of vitamin B3, was employed as a proline (Pro) bioisostere, generating 12 vitamin B3-MIF-1 hybrids. Nicotinoyl-l-leucylglycinamide (6c) emerged as a lead compound, promoting a 5.11-fold enhancement of dopamine potency at 0.01 nM and displaying neuroprotective activity at 50-100 μM in dopaminergic-differentiated SH-SY5Y cells. Additionally, Pro-to-Nic substitution showed no cytotoxicity in HepG2, reduced P-glycoprotein-mediated efflux, and preserved β-turn conformational propensity, supporting improved oral drug-like properties. Collectively, these findings identify 6c as a dual-acting lead and establish Nic as a privileged Pro surrogate for next-generation MIF-1-based PD therapeutics.

  • Open Access

    Proline Homologation in Melanostatin Neuropeptide: Discovery of Potent Modulators of the Dopamine D 2 Receptors

    by Ivo E. Sampaio-Dias, Hugo F. Costa-Almeida, Xavier C. Correia, Sara C. Silva-Reis, Vera M. Costa, José Brea, María I. Loza, José E. Rodríguez-Borges, Xerardo García-Mera

    Melanostatin (MIF-1) is a naturally occurring neuropeptide acting as a positive allosteric modulator (PAM) of dopamine D2 receptors (D2R), underscoring its potential for therapeutic use in central nervous system disorders associated with dopaminergic dysregulation, including depression, drug addiction, restless legs syndrome, tardive dyskinesia, and Parkinson's disease. In this work, a new series of MIF-1 analogs using l-pipecolic acid as an l-proline surrogate was synthesized and pharmacologically evaluated by functional assays at the D2R. In this series, methyl l-pipecolyl-l-leucylglycinate (9) was found to exhibit superior performance compared to MIF-1 by promoting a 4.1- and 4.2-fold increase of dopamine potency at 0.01 and 1 nM, respectively. In silico conformational studies demonstrate that 9 preferentially adopts a γ-turn, corroborating that neither the C-terminal carboxamide nor the postulated type II β-turn conformation is required for PAM activity. Toxicological assays in human dopaminergic SH-SY5Y neuronal cells show that this compound exhibits no significant toxicity up to 100 μM in the MTT reduction and neutral red uptake assays.


  • Telescoped One-Pot Strategy for the Assembly of cis-4-Hydroxy-l-Prolyl Amides

    by Ivo E. Sampaio-Dias, Sara C. Silva-Reis, Xavier Cruz Correia, Hugo F. Costa-Almeida, Beatriz L. Pires-Lima, Xerardo García-Mera


  • Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D2 Receptors

    by Sara C. Silva-Reis, Xavier C. Correia, Hugo F. Costa-Almeida, Beatriz L. Pires-Lima, Daiane Maronde, Vera M. Costa, Xerardo García-Mera, Luís Cruz, José Brea, María Isabel Loza, et al.

    This work describes the synthesis and pharmacological and toxicological evaluation of melanostatin (MIF-1) bioconjugates with amantadine (Am) via a peptide linkage. The data from the functional assays at human dopamine D2 receptors (hD2R) showed that bioconjugates 1 (EC50 = 26.39 ± 3.37 nM) and 2 (EC50 = 17.82 ± 4.24 nM) promote a 3.3- and 4.9-fold increase of dopamine potency, respectively, at 0.01 nM, with no effect on the efficacy (Emax = 100%). In this assay, MIF-1 was only active at the highest concentration tested (EC50 = 23.64 ± 6.73 nM, at 1 nM). Cytotoxicity assays in differentiated SH-SY5Y cells showed that both MIF-1 (94.09 ± 5.75%, p < 0.05) and carbamate derivative 2 (89.73 ± 4.95%, p < 0.0001) exhibited mild but statistical significant toxicity (assessed through the MTT reduction assay) at 200 μM, while conjugate 1 was found nontoxic at this concentration.